AS 203
Alternative Names: AS-203Latest Information Update: 07 Oct 2020
At a glance
- Originator AcuraStem
- Class Antidementias; Antisense oligonucleotides; Neuroprotectants
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Amyotrophic lateral sclerosis; Frontotemporal dementia
Highest Development Phases
- Research Amyotrophic lateral sclerosis; Frontotemporal dementia
Most Recent Events
- 24 Sep 2020 AS 203 is available for licensing as of 24 Sep 2020. https://acurastem.com/contact/contact-us (Acurastem website, September 2020)
- 24 Sep 2020 Early research in Amyotrophic lateral sclerosis in USA (Parenteral) before September 2020 (AcuraStem pipeline, September 2020)
- 24 Sep 2020 Early research in Frontotemporal dementia in USA (Parenteral) before September 2020 (AcuraStem pipeline, September 2020)